BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it will be presenting at the 8th Annual New York Stem Cell Summit on Tuesday, February 19th at 2:00 pm EST. The company’s Chief Medical Advisor, Prof. Eldad Melamed, MD, will discuss the latest scientific and clinical developments of NurOwn™, BrainStorm’s stem cell therapy candidate for ALS, including its recent acceleration to a Phase IIa dose-escalating trial by the Israeli Ministry of Health.
